Wavefront Field Mapping Reveals a Physiologic Network Between Drivers Where Ablation Terminates Atrial Fibrillation.


Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
08 2019
Historique:
entrez: 30 7 2019
pubmed: 30 7 2019
medline: 9 4 2020
Statut: ppublish

Résumé

Localized drivers are proposed mechanisms for persistent atrial fibrillation (AF) from optical mapping of human atria and clinical studies of AF, yet are controversial because drivers fluctuate and ablating them may not terminate AF. We used wavefront field mapping to test the hypothesis that AF drivers, if concurrent, may interact to produce fluctuating areas of control to explain their appearance/disappearance and acute impact of ablation. We recruited 54 patients from an international registry in whom persistent AF terminated by targeted ablation. Unipolar AF electrograms were analyzed from 64-pole baskets to reconstruct activation times, map propagation vectors each 20 ms, and create nonproprietary phase maps. Each patient (63.6±8.5 years, 29.6% women) showed 4.0±2.1 spatially anchored rotational or focal sites in AF in 3 patterns. First, a single (type I; n=7) or, second, paired chiral-antichiral (type II; n=5) rotational drivers controlled most of the atrial area. Ablation of 1 to 2 large drivers terminated all cases of types I or II AF. Third, interaction of 3 to 5 drivers (type III; n=42) with changing areas of control. Targeted ablation at driver centers terminated AF and required more ablation in types III versus I (P=0.02 in left atrium). Wavefront field mapping of persistent AF reveals a pathophysiologic network of a small number of spatially anchored rotational and focal sites, which interact, fluctuate, and control varying areas. Future work should define whether AF drivers that control larger atrial areas are attractive targets for ablation.

Sections du résumé

BACKGROUND
Localized drivers are proposed mechanisms for persistent atrial fibrillation (AF) from optical mapping of human atria and clinical studies of AF, yet are controversial because drivers fluctuate and ablating them may not terminate AF. We used wavefront field mapping to test the hypothesis that AF drivers, if concurrent, may interact to produce fluctuating areas of control to explain their appearance/disappearance and acute impact of ablation.
METHODS
We recruited 54 patients from an international registry in whom persistent AF terminated by targeted ablation. Unipolar AF electrograms were analyzed from 64-pole baskets to reconstruct activation times, map propagation vectors each 20 ms, and create nonproprietary phase maps.
RESULTS
Each patient (63.6±8.5 years, 29.6% women) showed 4.0±2.1 spatially anchored rotational or focal sites in AF in 3 patterns. First, a single (type I; n=7) or, second, paired chiral-antichiral (type II; n=5) rotational drivers controlled most of the atrial area. Ablation of 1 to 2 large drivers terminated all cases of types I or II AF. Third, interaction of 3 to 5 drivers (type III; n=42) with changing areas of control. Targeted ablation at driver centers terminated AF and required more ablation in types III versus I (P=0.02 in left atrium).
CONCLUSIONS
Wavefront field mapping of persistent AF reveals a pathophysiologic network of a small number of spatially anchored rotational and focal sites, which interact, fluctuate, and control varying areas. Future work should define whether AF drivers that control larger atrial areas are attractive targets for ablation.

Identifiants

pubmed: 31352796
doi: 10.1161/CIRCEP.118.006835
pmc: PMC6666420
mid: NIHMS1532777
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e006835

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL122384
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL145500
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL103800
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL083359
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL145017
Pays : United States
Organisme : NHLBI NIH HHS
ID : F32 HL144101
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

J Cardiovasc Electrophysiol. 2005 Nov;16(11):1125-37
pubmed: 16302892
Eur Heart J. 2009 May;30(9):1105-12
pubmed: 19270341
J Am Coll Cardiol. 2012 Aug 14;60(7):628-36
pubmed: 22818076
Pacing Clin Electrophysiol. 2012 Dec;35(12):1436-43
pubmed: 23035703
Chaos. 2013 Jun;23(2):023113
pubmed: 23822478
JAMA. 2014 Feb 5;311(5):498-506
pubmed: 24496537
J Cardiovasc Electrophysiol. 2014 Sep;25(9):921-929
pubmed: 24948520
Circulation. 2014 Aug 12;130(7):530-8
pubmed: 25028391
IEEE Trans Biomed Eng. 2015 Jan;62(1):296-302
pubmed: 25148659
Eur Heart J. 2015 Sep 14;36(35):2390-401
pubmed: 26059724
Int J Cardiol. 2015 Nov 15;199:407-14
pubmed: 26253050
Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1325-33
pubmed: 26359479
Circulation. 2016 Aug 9;134(6):486-98
pubmed: 27462069
Circ Arrhythm Electrophysiol. 2016 Nov;9(11):
pubmed: 27906655
Phys Rev E. 2016 Nov;94(5-1):050401
pubmed: 27967050
Heart Rhythm. 2017 Apr;14(4):476-483
pubmed: 28011328
J Am Coll Cardiol. 2017 Jan 24;69(3):303-321
pubmed: 28104073
J Cardiovasc Electrophysiol. 2017 Jun;28(6):615-622
pubmed: 28185348
J Am Coll Cardiol. 2017 Mar 14;69(10):1247-1256
pubmed: 28279291
Circ Res. 2017 Apr 28;120(9):1396-1398
pubmed: 28450363
Circ Arrhythm Electrophysiol. 2017 May;10(5):e004899
pubmed: 28500175
Heart Rhythm. 2017 Oct;14(10):e275-e444
pubmed: 28506916
J Cardiovasc Electrophysiol. 2017 Dec;28(12):1371-1378
pubmed: 28800192
J Cardiovasc Electrophysiol. 2017 Dec;28(12):1423-1432
pubmed: 28862787
Europace. 2018 Nov 1;20(FI_3):f366-f376
pubmed: 29267853
Circ Arrhythm Electrophysiol. 2018 Jan;11(1):e005258
pubmed: 29330332
Europace. 2018 Jul 1;20(7):1099-1106
pubmed: 29340595
J Cardiovasc Electrophysiol. 2018 May;29(5):687-695
pubmed: 29377478
JACC Clin Electrophysiol. 2018 Jan;4(1):124-134
pubmed: 29387810
Circ Arrhythm Electrophysiol. 2018 May;11(5):e006119
pubmed: 29743170
JACC Clin Electrophysiol. 2017 Mar;3(3):207-216
pubmed: 29759514
JACC Clin Electrophysiol. 2016 Nov;2(6):667-678
pubmed: 29759744
Circ Arrhythm Electrophysiol. 2018 Jun;11(6):e005846
pubmed: 29884620
Circulation. 1994 Apr;89(4):1665-80
pubmed: 8149534

Auteurs

George Leef (G)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Fatemah Shenasa (F)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Neal K Bhatia (NK)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Albert J Rogers (AJ)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

William Sauer (W)

Department of Medicine, University of Colorado, Denver (W.S., E.A.).

John M Miller (JM)

Department of Medicine, University of Indiana, Indianapolis (J.M.M.).

Mark Swerdlow (M)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Mallika Tamboli (M)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Mahmood I Alhusseini (MI)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Erin Armenia (E)

Department of Medicine, University of Colorado, Denver (W.S., E.A.).

Tina Baykaner (T)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Johannes Brachmann (J)

Department of Cardiology, Klinikum Coburg, Germany (J.B.).

Mintu P Turakhia (MP)

Department of Medicine, Veterans Affairs Palo Alto Health Care System, CA (M.P.T.).

Felipe Atienza (F)

Departamento de Cardiologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain (F.A.).

Wouter-Jan Rappel (WJ)

Department of Physics, University of California, San Diego (W.J.R.).

Paul J Wang (PJ)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Sanjiv M Narayan (SM)

Department of Medicine, Stanford University, California (G.L., F.S., N.K.B., A.J.R., M.S., M.T., M.I.A., T.B., P.J.W., S.M.N.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH